#DIA2018 | Alberto Grignolo on Expedited Pathways

July 3, 2018
From the floor at #DIA2018 - PAREXEL Corporate VP Alberto Grignolo shares his views on the proliferation of expedited regulatory approval pathways in key markets and its implications for global clinical development.
Previous Video
PAREXEL® Regulatory Consulting Services
PAREXEL® Regulatory Consulting Services

An overview of PAREXEL’s Regulatory Consulting services

Next Video
Michelle Hoiseth on the Importance of Real-World Data
Michelle Hoiseth on the Importance of Real-World Data

Real-World Data provides important opportunities for the drug development industry. Michelle Hoiseth, PAREX...